nach oben

Osteoporosis International

Erschienen in:

01.01.2007 | Original Article

Epidemiology, treatment and costs of osteoporosis in Germany—the BoneEVA Study

verfasst von: B. Häussler, H. Gothe, D. Göl, G. Glaeske, L. Pientka, D. Felsenberg

Erschienen in: Osteoporosis International | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

Introduction

In Germany, accurate data on the prevalence and treatment of osteoporosis, as well as the cost of this illness, are not available. The aim of this study is to give a valid estimation of these items for the year 2003.

Methods

Routine data from a German sickness fund covering 1.5 million beneficiaries and billing data for outpatient visits were used to obtain estimates of prevalence for osteoporosis. Claims data for patients with osteoporosis (M80, M81) or an osteoporosis-related fracture diagnosis (S22, S32, S42, S52, S72, S82) or treatment with anti-osteoporosis drugs were examined. Costs were calculated from the perspective of the German health insurance system and the German nursing care insurance system, respectively. Only direct costs of osteoporosis were considered.

Results

In 2003, 7.8 million Germans (6.5 million women) were affected by osteoporosis. Of them, 4.3% experienced at least one clinical fracture. Only 21.7% were treated with an anti-osteoporosis drug. The total direct costs attributable to osteoporosis amounted to €5.4 billion.

Conclusion

This study confirms that osteoporosis is underdiagnosed, undertreated and imposes a considerable economic burden on the health system in Germany. Effective strategies for the prevention and management of this disease are needed.

Patients with an encounter due to Morbus Paget (ICD10: M88) and/or hypercalcaemia (ICD10: E83.5*) and/or tumour induced osteoporosis (ICD10: M90.7*) were excluded from the analysis.

[No authors listed] (1993) Consensus Development Conference on Osteoporosis. Hong Kong, April 1–2, 1993. Am J Med 95(5A):1S–78S

Melton LJ (1988) Osteoporosis: etiology, diagnosis and management. In: Riggs BL, Melton LJ (eds) Epidemiology of fractures. Raven Press, New York, pp 133–154

Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP (1997) Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 12(11):1761–1768PubMedCrossRef

Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27(5):585–590PubMedCrossRef

Ballard PA, Purdie DW, Langton CM, Steel SA, Mussurakis S (1998) Prevalence of osteoporosis and related risk factors in UK women in the seventh decade: osteoporosis case finding by clinical referral criteria or predictive model? Osteoporos Int 8(6):535–539PubMedCrossRef

O’Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ (1996) The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 11(7):1010–1018PubMedCrossRef

DAGO (1998) Die Empfehlungen der Deutschen Arbeitsgemeinschaft Osteoporose. Klin Pharmakol Aktuell 9:47–53

Dewitz HD (2004) Osteoporose—Diagnostik, Prävention und Therapie. KV-Blatt 11

Melton LJ 3rd, Thamer M, Ray NF, Chan JK, Chesnut CH 3rd, Einhorn TA, Johnston CC, Raisz LG, Silverman SL, Siris ES (1997) Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 12(1):16–23PubMedCrossRef

10.

Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D (1997) Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 7(4):390–406PubMedCrossRef

11.

Lippuner K, von Overbeck J, Perrelet R, Bosshard H, Jaeger P (1997) Incidence and direct medical costs of hospitalizations due to osteoporotic fractures in Switzerland. Osteoporos Int 7(5):414–425PubMedCrossRef

12.

Glaeske G, Jahnsen K (2005) GEK—Arzneiverordnungsreport. Asgard Verlag, St. Augustin, Germany

13.

Brecht JG, Schädlich PK (2000) Burden of illness imposed by osteoporosis in Germany. Eur J Health Econom 1(1):26–32CrossRef

14.

Rote Liste Service GmbH (2003) Rote Liste WinR. Arzneimittelverzeichnis für Deutschland. Editio Cantor Verlag, Aulendorf/Württ

15.

DVO (2003) Osteoporose bei Frauen nach der Menopause und im höheren Lebensalter. Prophylaxe, Diagnose, Therapie—Empfehlungen des Dachverbandes der deutschsprachigen osteologischen Fachgesellschaften

16.

AkdÄ H (2003) Therapieempfehlungen der Arzneimittelkommission der deutschen Ärzteschaft: Osteoporose. Arzneiverordnung in der Praxis

17.

Centers for Disease Control and Prevention (CDC) (1998) Osteoporosis among estrogen-deficient women—United States 1988–1994. Morb Mortal Wkly Rep 47(45):969–973

18.

Oberender PO, Fritschi DA (2003) Disease Management und Osteoporose: Versorgungsmängel bei einer relevanten Frauenkrankheit. Dtsch Ärztebl 100(25A):1728–1733

19.

Castel H, Bonneh DY, Sherf M, Liel Y (2001) Awareness of osteoporosis and compliance with management guidelines in patients with newly diagnosed low-impact fractures. Osteoporos Int 12(7):559–564PubMedCrossRef

20.

Freedman KB, Kaplan FS, Bilker WB, Strom BL, Lowe RA (2000) Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am 82-A(8):1063–1070PubMed

21.

IPSOS-SRL (2000) How fragile is her future? Osteoporosis Research in Partnership with International Osteoporosis Foundation (IOF)

22.

Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC 3rd, Yanover MJ (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323(2):73–79PubMedCrossRef

23.

Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333(22):1437–1443PubMedCrossRef

24.

Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280(24):2077–2082PubMedCrossRef

25.

Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344–1352PubMedCrossRef

26.

Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1):83–91PubMedCrossRef

27.

McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344(5):333–340PubMedCrossRef

28.

Dietrich ES, Jopp R, Schreier U, Gilge R, Bartmann P, Berthold H (2005) Drug expenditures resulting from the implementation of clinical practice guideline in Germany. Gesundh ökon Qual manag 10(1):35–43CrossRef

29.

Krappweis J, Rentsch A, Schwarz UI, Krobot KJ, Kirch W (1999) Outpatient costs of osteoporosis in a national health insurance population. Clin Ther 21(11):2001–2014PubMedCrossRef

30.

Gotte S, Dittmar K (2001) Epidemiology and costs of osteoporosis (in German). Orthopade 30(7):402–404PubMedCrossRef

31.

Bestehorn K, Zink A, Dreher R (2002) Drug therapy in postmenopausal osteoporosis. An analysis of healty service delivery (in German). Z Arztl Fortbild Qualitatssich 96(10):699–704PubMed

32.

Gehlbach SH, Fournier M, Bigelow C (2002) Recognition of osteoporosis by primary care physicians. Am J Public Health 92(2):271–273PubMedCrossRef

33.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333PubMedCrossRef

34.

Kanis JA, Dawson A, Oden A, Johnell O, de Laet C, Jonsson B (2001) Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 12(5):356–361PubMedCrossRef

35.

Iglesias CP, Torgerson DJ, Bearne A, Bose U (2002) The cost utility of bisphosphonate treatment in established osteoporosis. QJM 95(5):305–311PubMedCrossRef

36.

Trombetti A, Herrmann F, Hoffmeyer P, Schurch MA, Bonjour JP, Rizzoli R (2002) Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int 13(9):731–737PubMedCrossRef

Titel: Epidemiology, treatment and costs of osteoporosis in Germany—the BoneEVA Study
verfasst von: B. Häussler
H. Gothe
D. Göl
G. Glaeske
L. Pientka
D. Felsenberg
Publikationsdatum: 01.01.2007
Verlag: Springer-Verlag
Erschienen in: Osteoporosis International / Ausgabe 1/2007
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-006-0206-y

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2007

Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment

Volumetric bone mineral density and bone size in sleep-deprived individuals

Severity of vertebral fracture reflects deterioration of bone microarchitecture

Bone mineral density and mandibular bone quality in patients receiving dental implants

Cost-effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference model